Two CRLs, both manufacturing-only: OLC approval hinges on whether FDA clears the vendor facility

Unicycive is a clinical-stage company developing OLC, an oral phosphate binder for dialysis patients, which is not yet approved.

OLC is an oral phosphate binder for dialysis patients with dangerous blood phosphorus buildup, and it has now received two Complete Response Letters from FDA for the same third-party manufacturing deficiency, with no clinical or safety concerns ever raised. The thesis resolves on whether the vendor facility passes FDA inspection, enabling resubmission and approval. Ardelyx's tenapanor, a competing phosphate-reduction agent already approved in the same indication, narrows the commercial runway even if the regulatory hurdle clears.